Skip to main content
. 2006 May;168(5):1631–1641. doi: 10.2353/ajpath.2006.050521

Figure 4.

Figure 4

Brk expression and impact on in vitro proliferation and survival and in vivo tumorigenicity in the Brk-transfected lymphoid cells. A: Brk protein expression in nuclei versus cytoplasm in the IL-3-dependent BaF3 lymphoid cells transfected with either WT Brk construct or empty vector (E. vec). The depicted Brk-WT, Brk-kinase-inactive (K219M) mutant, and vector-expressing BaF3 cells cultured in the presence of either complete (10% FBS and IL-3), cytokine-depleted (10% FBS alone), or serum-depleted (IL-3 and 2% BSA) medium and evaluated for BrdU incorporation (B) or DNA fragmentation (TUNEL assay; D). The Brk-WT- and vector-expressing BaF3 cells cultured in the complete, cytokine-, or serum-depleted medium were evaluated for propidium iodide incorporation (C) and cell-surface annexin V expression (E). F: SCID-beige mice (five per group) were inoculated intraperitoneally with either Brk-WT- or vector-expressing BaF3 cells and followed for evidence of morbidity. The diagram depicts survival time of both groups with the mice injected with Brk-expressing BaF3 cells developing a wide-spread lymphoproliferative disorder within 5 weeks and the mice injected with vector-carrying BaF3 cells showing no sign of disease by week 17.